Prostate Cancer: Bipolar Androgen Therapy (BAT)

madman

Super Moderator
To view this content we will need your consent to set third party cookies.
For more detailed information, see our cookies page.

Screenshot (27127).png

Summary

Prostate Cancer Lab #56 focuses on Bipolar Androgen Therapy (BAT) as a potential treatment for castration-resistant prostate cancer. The therapy involves alternating between high-dose testosterone injections and the continuation of testosterone-suppressing drugs. BAT has shown positive results in some patients, but it may not be suitable for everyone.

Highlights

  • BAT has extended the lives of some patients and improved their quality of life.
  • PSA levels may initially increase before decreasing during BAT treatment, so it is important not to panic.
  • Response rates to BAT vary among patients, with approximately one-third experiencing a significant decline in PSA levels, one-third reaching a stable plateau, and one-third not responding to the therapy.
  • Genetic markers such as BRCA2 and p53 mutations may predict better responses to BAT.
  • The optimal timing for BAT treatment and the choice of hormone therapy are still areas of ongoing research and discussion.
 




 

Online statistics

Members online
4
Guests online
382
Total visitors
386

Latest posts

Back
Top